Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98

Repligen Co. (NASDAQ:RGEN - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $160.98, but opened at $154.59. Repligen shares last traded at $156.00, with a volume of 183,643 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on RGEN shares. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a research note on Thursday, February 22nd. JPMorgan Chase & Co. increased their target price on shares of Repligen from $170.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, December 20th. Finally, KeyCorp increased their target price on shares of Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $196.70.

Repligen Stock Down 2.4 %

The company has a market cap of $8.77 billion, a PE ratio of 219.36, a P/E/G ratio of 5.38 and a beta of 1.02. The company's 50 day moving average is $190.02 and its 200 day moving average is $173.20. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm's revenue was down 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 EPS. As a group, analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the firm's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now directly owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders have sold 25,597 shares of company stock valued at $5,039,532 in the last 90 days. Company insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.5% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company's stock valued at $1,663,000 after purchasing an additional 159 shares during the period. International Assets Investment Management LLC grew its position in shares of Repligen by 18,449.1% in the 4th quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company's stock worth $10,539,000 after buying an additional 58,299 shares during the last quarter. American Century Companies Inc. grew its position in shares of Repligen by 97.5% in the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company's stock worth $34,648,000 after buying an additional 107,570 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Repligen in the 4th quarter worth approximately $2,625,000. Finally, Atria Investments Inc purchased a new position in shares of Repligen in the 3rd quarter worth approximately $1,046,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.